A single antibody could be the key to treating multiple myeloma, or cancer of the blood, currently without cure or long-term treatment.
“We tested the antibody in various ways, including on tumour cells from myeloma patients that have been transplanted into mice. The tests showed that the antibody is able to destroy myeloma cells”, explains Markus Hansson, a researcher at Lund University in Sweden.
Using a ‘biological library’ of thousands of antibodies from the company BioInvent in Lund, the team singled out antibody BI-505, shown to have a powerful effect on the tumour cells in both cell studies and animal experiments. It has also been tested in an initial safety study on seriously ill patients, and a study of its treatment effects has just started.
“This study will include patients who have just been diagnosed and therefore still feel fairly well. We want to test the antibody treatment before the patients are treated with any other drugs”, says Markus Hansson.
Today there are a number of drugs to treat multiple myeloma, but no cure. None of the drugs are able to eradicate the disease, meaning cancer cells increase in number after a period of remission. Survival has been extended with new treatments, but less than half of all patients live longer than five years from diagnosis.
Myeloma occurs when a specific type of cell in the bone marrow is converted into tumour cells. Blood formation is disrupted and patients suffer from a lack of blood resulting in fatigue. The bones can be weakened with a risk of fractures and compacted vertebrae, and patients sometimes suffer kidney failure as a result of the disease.
Antibodies are a part of the immune system, fighting off foreign bodies. Antibody-based drugs are now used to treat certain inflammatory diseases and types of cancer.
The treatment study in Lund will involve 15 patients and is expected to be completed this year.
The Latest Bing News on:
- Time To Book Profit In Fate Therapeutics Stock After A 5x Rally?on January 24, 2021 at 8:29 pm
We believe the stock has rallied meaningfully and it is likely to see downside after the recent uptick. Our dashboard, ‘ What Factors Drove 1771% Change in Fate Therapeutics Stock between 2017 end and ...
- 3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond)on January 24, 2021 at 3:48 am
A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and ...
- CAR-T for Myeloma Excites at ASH, but Questions Remainon January 22, 2021 at 10:02 am
MedPage Today has brought together three expert leaders in the field: moderator Vinay Prasad, MD, is joined by Aaron Goodman, MD, and Al-Ola Abdallah, MD, for a virtual roundtable discussion on the ...
- Renal insufficiency may worsen multiple myeloma outcomeson January 22, 2021 at 9:37 am
(HealthDay)—For patients with multiple myeloma (MM), those with renal insufficiency (RI) have an increased risk for disease progression or death, according to a systematic review and meta-analysis ...
- Antisense Oligo Targets IRF4 Gene to Treat Multiple Myelomaon January 21, 2021 at 7:07 am
Past studies have shown that high IRF4 levels are associated with lower overall survival rates for patients with multiple myeloma.
- Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in miceon January 20, 2021 at 11:54 am
Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that ...
- Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in miceon January 20, 2021 at 10:13 am
A new study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma.
- Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myelomaon January 20, 2021 at 8:07 am
Ionis teamed up with researchers at the University of California, San Diego to inhibit the gene IRF4 in multiple myeloma using an antisense oligonucleotide. The drug, called ION251, significantly cut ...
- Talquetamab Shows Encouraging Responses in R/R Multiple Myelomaon January 19, 2021 at 9:21 pm
Data presented at December's American Society of Hematology virtual meeting showed a high response rate with talquetamab along with tolerable safety for patients with relapsed/refractory multiple ...
- Global Multiple Myeloma Therapy Market 2020 Definition, Size, Share, Segmentation and Forecast data by 2025on January 17, 2021 at 11:52 am
The latest market research report titled Global Multiple Myeloma Therapy Market 2020 by Company, Type and Application, Forecast to 2025 reveals the overview of the global industry, encompassing the ...
The Latest Google Headlines on:
The Latest Bing News on:
Cancer of the blood
- HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)on January 24, 2021 at 3:29 pm
Picture A shows a patient’s TNBC biopsy scanned by HistoIndex’s stain-free AI digital pathology platform. The collagen fibers as well as changes in collagen structures are highlighted in green when ...
- Soccer players team up to help one of their own, a 9-year-old girl fighting a rare canceron January 24, 2021 at 8:01 am
The nonprofit Palm Beach Gardens Youth Athletic Association is collecting donations for Luna Perrone, a softball and soccer player.
- Lung cancer symptoms: A hoarse voice ‘not a commonly known sign’ of the diseaseon January 23, 2021 at 3:56 am
LUNG cancer is one of the most common and serious types of cancer. But like all cancer, there's currently no cure. This makes spotting symptoms very important - earlier diagnosis means a higher chance ...
- COVID more severe with blood cancerson January 22, 2021 at 3:38 pm
With a cough, fever and low oxygen, he spent five days in the hospital. He knew that people with blood and bone marrow disorders are less likely to survive.
- Researchers identify novel target that could improve the safety of CAR T cell therapy for pancreatic canceron January 22, 2021 at 6:51 am
Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the ...
- Blood Cancer Drugs Market Size 2020 Analysis and In-depth Research on Trends, Emerging Growth Factors and Forecast to 2024on January 22, 2021 at 5:59 am
Jan (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Blood cancers, or hematologic ...
- Target of New Cancer Treatment Valid for Breast as Well as Blood Cancers: Study (image)on January 21, 2021 at 7:25 am
University of Alberta oncology researcher John Mackey (left) and cell biologist Luc Berthiaume are collaborators on new research showing that PCLX-001, an anti-cancer drug set to begin clinical trials ...
- Worldwide Blood Cancer Drugs Industry to 2026 - Featuring Amgen, AstraZeneca and Astellas Pharma Among Otherson January 20, 2021 at 11:45 am
Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering. The report on blood cancer drugs market is a comprehensive study ...
- Global Blood Cancer Drugs Market (2020 to 2026) - Industry Analysis, Trends, Market Size, and Forecasts - ResearchAndMarkets.comon January 19, 2021 at 9:59 pm
ResearchAndMarkets.com The “Blood Cancer Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added to ResearchAndMarkets.com’s offering. The report ...
- Target of new cancer treatment valid for breast as well as blood cancers: studyon January 19, 2021 at 9:00 pm
Newly published research shows that a new anti-cancer drug developed at the University of Alberta, set to begin human trials this year, may work against breast cancer as well as blood cancer.